# A 6-week Study to Evaluate the Safety and Efficacy of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD

> **NCT03536390** · PHASE4 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03536390
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-09-19
- **Primary completion:** 2021-04-22
- **Final completion:** 2021-04-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was cancelled prior to the enrollment of any participants.
- **Last updated:** 2018-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03536390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03536390, "A 6-week Study to Evaluate the Safety and Efficacy of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03536390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*